PreeclampsiaNCT06337799
Use of Allied-health Professionals to Improve Treatment of Disease
A study testing Research Pharmacist in people with Preeclampsia, run by University of Iowa.
Trial summary
The goal of this clinical trial is to learn if allied-health professionals can recruit and follow research participants, sustain engagement, and improve and diagnose treatment of diseases by facilitating transitions of care. Read more about this study
- Who is it for?
- Ages 18 to 55 years, women only
- Conditions the study is for
- Preeclampsia
- What is being tested?
- Research Pharmacist
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- Oct 2026to Mar 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Biological mothers delivering at UIHC or attending a well-child visit for an infant between 1 month and 9 months
- Preeclampsia during pregnancy
- Preceived prenatal care at UIHC
- Owns a smartphone
Who cannot join
- Arm circumference greater than 17 inches
- Prisoner status
- Unable to provide own written informed consent
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Use of Non-physician Allied-health Professionals to Recruit (and Follow) Research Participants, Sustain Engagement, and Improve and Diagnose Treatment of Diseases by Facilitating Transitions of Care
The goal of this clinical trial is to learn if allied-health professionals can recruit and follow research participants, sustain engagement, and improve and diagnose treatment of diseases by facilitating transitions of care.
Participants will:
Take their blood pressure at home and return it to the research team; Follow up with a research pharmacist for 12 months; Return for a follow up visit after 12 months.
Read the detailed description
After consent, a research pharmacist will virtually monitor the participant's blood pressure until the 12-month follow up visit. The research pharmacists will have access to the participant's electronic medical records to monitor and document medications and clinic blood pressures for analysis . Participants will be asked to measure and return 14 blood pressure measurements (2x per day for 7 days) using our text messaging platform. They will be allowed to choose the times that they are sent reminders to measure their blood pressure. If a participant has blood pressure values sufficient for a hypertension diagnosis, the pharmacist will communicate via electronic medical record with the participant's primary care team. If they do not have a primary care provider, the pharmacist will facilitate finding one. The pharmacist will continue monitoring the participant and making recommendations to the primary care team through the electronic medical record to quickly adjust therapy to improve blood pressure control. The pharmacists will typically contact the participants (via participant's choice of phone, text, or email) every 2-3 weeks while their hypertension is uncontrolled. Once under control, the pharmacist will continue to contact the participant at least every 2 months to support adherence and reassess control.
- Conditions
- Preeclampsia
- Being tested
- Research Pharmacist
- Medical subject headings
- Pre-Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Research PharmacistBehavioural
The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
| Study group | Role | What they receive |
|---|---|---|
| Research Pharmacist Monitoring | Experimental | The research pharmacist will help the mother find a primary care physician if she doesn't have one and discuss strategies to lower blood pressure, if needed. The pharmacist interactions will occur 7 days after enrollment and then approximately every 2 weeks to 2 months during 12 months of follow up, depending on blood pressure control. They may recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed. Receives: Behavioral: Research Pharmacist |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Subjects at Risk for Hypertension
We will calculate the number of participants who are at risk for hypertension during the course of the intervention.
Measured: Through study completion, an average of 12 months
Number of Subjects Exposed to a Screening Clinic
We will calculate the number of participants who visited a screening clinic during the course of the intervention.
Measured: Through study completion, an average of 12 months
Number of Subjects Screened at a Screening Clinic
We will calculate the number of participants who were screened at a screening clinic during the intervention.
Measured: Through study completion, an average of 12 months
Number of Subjects Followed-Up by the Research Pharmacist
We will calculated the number of participants who were followed-up by a research pharmacist during the intervention.
Measured: Through study completion, an average of 12 months
Number of Subjects Diagnosed with Hypertension
We will calculate the number of participants who were diagnosed with hypertension by their provider during the intervention.
Measured: Through study completion, an average of 12 months
Number of Subjects Treated for Hypertension, if Diagnosed
We will calculate the number of participants who were treated for their hypertension diagnosis by their provider, if they were diagnosed with hypertension, during the intervention.
Measured: Through study completion, an average of 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2024
- Study startOct 2026 (estimated)
- Primary completionMar 2030 (estimated)
- Study completionMar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PreeclampsiaStudies of the same condition, open and under way.
- More trials run by University of IowaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Iowa
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Philip Polgreen, University of Iowa
- Investigators
- Philip M Polgreen, MD, Principal investigator, University of Iowa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06337799
- Sponsor's protocol ID
- 202210411
- Status last verified
- Jun 2026
- First submitted
- 22 Mar 2024
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of Non-physician Allied-health Professionals to Recruit (and Follow) Research Participants, Sustain Engagement, and Improve and Diagnose Treatment of Diseases by Facilitating Transitions of Care
- ClinicalTrials.gov ID
- NCT06337799
- Acronym / sponsor ID
- 202210411
- Conditions
- Preeclampsia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of IowaUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- Mar 2030 (estimated)
- Study completion
- Mar 2030 (estimated)
- First posted
- 29 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if allied-health professionals can recruit and follow research participants, sustain engagement, and improve and diagnose treatment of diseases by facilitating transitions of care.
Participants will:
Take their blood pressure at home and return it to the research team; Follow up with a research pharmacist for 12 months; Return for a follow up visit after 12 months.
Detailed description
After consent, a research pharmacist will virtually monitor the participant's blood pressure until the 12-month follow up visit. The research pharmacists will have access to the participant's electronic medical records to monitor and document medications and clinic blood pressures for analysis . Participants will be asked to measure and return 14 blood pressure measurements (2x per day for 7 days) using our text messaging platform. They will be allowed to choose the times that they are sent reminders to measure their blood pressure. If a participant has blood pressure values sufficient for a hypertension diagnosis, the pharmacist will communicate via electronic medical record with the participant's primary care team. If they do not have a primary care provider, the pharmacist will facilitate finding one. The pharmacist will continue monitoring the participant and making recommendations to the primary care team through the electronic medical record to quickly adjust therapy to improve blood pressure control. The pharmacists will typically contact the participants (via participant's choice of phone, text, or email) every 2-3 weeks while their hypertension is uncontrolled. Once under control, the pharmacist will continue to contact the participant at least every 2 months to support adherence and reassess control.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Research Pharmacist Monitoring | Experimental | Behavioral: Research PharmacistThe research pharmacist will help the mother find a primary care physician if she doesn't have one and discuss strategies to lower blood pressure, if needed. The pharmacist interactions will occur 7 days after enrollment and then approximately every 2 weeks to 2 months during 12 months of follow up, depending on blood pressure control. They may recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Biological mothers delivering at UIHC or attending a well-child visit for an infant between 1 month and 9 months
- Preeclampsia during pregnancy
- Preceived prenatal care at UIHC
- Owns a smartphone
Key exclusion criteria (3 listed)
- Arm circumference greater than 17 inches
- Prisoner status
- Unable to provide own written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Research PharmacistThe goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers. | Behavioural | Research Pharmacist Monitoring |
Primary outcome
Number of Subjects at Risk for Hypertension
Time frame: Through study completion, an average of 12 months
We will calculate the number of participants who are at risk for hypertension during the course of the intervention.
Number of Subjects Exposed to a Screening Clinic
Time frame: Through study completion, an average of 12 months
We will calculate the number of participants who visited a screening clinic during the course of the intervention.
Number of Subjects Screened at a Screening Clinic
Time frame: Through study completion, an average of 12 months
We will calculate the number of participants who were screened at a screening clinic during the intervention.
Number of Subjects Followed-Up by the Research Pharmacist
Time frame: Through study completion, an average of 12 months
We will calculated the number of participants who were followed-up by a research pharmacist during the intervention.
Number of Subjects Diagnosed with Hypertension
Time frame: Through study completion, an average of 12 months
We will calculate the number of participants who were diagnosed with hypertension by their provider during the intervention.
Number of Subjects Treated for Hypertension, if Diagnosed
Time frame: Through study completion, an average of 12 months
We will calculate the number of participants who were treated for their hypertension diagnosis by their provider, if they were diagnosed with hypertension, during the intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
Related trials for Preeclampsia
Recruiting
Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
Postpartum Exercise, Cardiometabolic Health
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Philip M Polgreen, MD principal investigator
University of Iowa
Questions about this trial
What is this clinical trial studying?
A study testing Research Pharmacist in people with Preeclampsia, run by University of Iowa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philip M Polgreen, MD (319-384-6194, philip-polgreen@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Subjects at Risk for Hypertension (time frame: Through study completion, an average of 12 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.